Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | TERT | O14746 | 10/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4750052 | 0.98 | ALDH1A1 (0.73) | ALDH1A1KMT2ALMNAPOLBMEN1 | |
| SCHEMBL4749143 | 0.91 | ALDH1A1 (0.58) | ALDH1A1KMT2ALMNAPOLBMEN1 | |
| SCHEMBL5151404 | 0.88 | TP53 (0.74) | ALDH1A1LMNATERTMAPT | |
| SCHEMBL4749808 | 0.87 | ATM (0.75) | LMNAPOLBTERTALOX15ATM | |
| SCHEMBL23291376 | 0.85 | ALDH1A1 (0.63) | ALDH1A1KMT2ALMNAPOLBMEN1 | |
| SCHEMBL14924419 | 0.84 | KMT2A (0.94) | ALDH1A1KMT2ALMNAPOLBMEN1 | |
| SCHEMBL14355560 | 0.84 | KMT2A (0.74) | ALDH1A1KMT2ALMNAPOLBMEN1 | |
| SCHEMBL3585599 | 0.84 | TP53 (0.78) | ALDH1A1KMT2ALMNAPOLBMEN1 | |
| SCHEMBL1409462 | 0.84 | KDM4E (0.71) | ALDH1A1KMT2ALMNAPOLBMEN1 | |
| SCHEMBL14924020 | 0.84 | KMT2A (0.68) | ALDH1A1KMT2ALMNAPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011162515-A2 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHD3ITION OF TYROSINE KINASE ACTIVITY | HANMI HOLDINGS CO. , LTD. (KR) | 2011-12-29 | — | — | WO | disclosed |
| WO-2008122667-A2 | UREYLENE DERIVATIVES | SCHOOL OF PHARMACY (GB) | 2008-10-16 | — | — | WO | disclosed |
| US-7300930-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-27 | — | — | US | disclosed |
| US-20070037862-A1 | inhibitors of polo-like kinases; (4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)-[3-ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetonitrile; cancer, auto-immune diseases, cardiovascular diseases | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037862-A1 | inhibitors of polo-like kinases; (4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)-[3-ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetonitrile; cancer, auto-immune diseases, cardiovascular diseases | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | US | disclosed |
| US-7160896-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-01-09 | — | — | US | disclosed |
| US-20060111389-A1 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-05-25 | — | — | US | disclosed |
| US-20030207909-A1 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037862-A1 | inhibitors of polo-like kinases; (4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)-[3-ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetonitrile; cancer, auto-immune diseases, cardiovascular diseases | PLK2, PLK4, PDXK | ALDH1A1 3013/4885KMT2A 849/4885LMNA 841/4885 |
| US-20030207909-A1 | Therapeutic acridone and acridine compounds | NAT1, TERT, CCNA1 | ALDH1A1 75/4885KMT2A 1152/4885LMNA 102/4885 |
| US-20060111389-A1 | Therapeutic acridone and acridine compounds | TERT, ACIN1, NAT1 | ALDH1A1 63/4885KMT2A 1398/4885LMNA 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.